SCHEMBL3559385

SCHEMBL3559385

[CH2]C(=O)c1ccccc1NC(=O)C1CC1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.59
▸ HPGD P15428 2/20 0.59
▸ KDM4E B2RXH2 1/20 0.59
▸ NPSR1 Q6W5P4 1/20 0.59
▸ HSD17B10 Q99714 1/20 0.59
▸ GAA P10253 2/20 0.53
▸ PKM P14618 1/20 0.53
▸ CETP P11597 1/20 0.51
▸ HDAC3 O15379 1/20 0.51
▸ HDAC1 Q13547 1/20 0.51
▸ HDAC2 Q92769 1/20 0.51
▸ RXFP1 Q9HBX9 7/20 0.51
▸ MAPT P10636 2/20 0.50
▸ LMNA P02545 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ MEN1 O00255 1/20 0.47
▸ GFER P55789 1/20 0.47
▸ KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28170369 0.84 ALDH1A1 (0.60) ALDH1A1HPGDKDM4ENPSR1HSD17B10
SCHEMBL16404476 0.84 ALDH1A1 (0.60) ALDH1A1HPGDKDM4ENPSR1HSD17B10
SCHEMBL3559389 0.83 ALDH1A1 (0.63) ALDH1A1HPGDKDM4ENPSR1HSD17B10
SCHEMBL21724826 0.83 SIRT2 (0.63) ALDH1A1HPGDKDM4ENPSR1HSD17B10
SCHEMBL11734795 0.78 ALDH1A1 (0.70) ALDH1A1HPGDKDM4ENPSR1HSD17B10
SCHEMBL11729230 0.78 ALDH1A1 (0.66) ALDH1A1HPGDKDM4ENPSR1HSD17B10
SCHEMBL7814976 0.77 ALDH1A1 (0.68) ALDH1A1HPGDKDM4ENPSR1HSD17B10
SCHEMBL11732563 0.77 ALDH1A1 (0.68) ALDH1A1HPGDKDM4ENPSR1HSD17B10
SCHEMBL11732914 0.77 ALDH1A1 (0.68) ALDH1A1HPGDKDM4ENPSR1HSD17B10
SCHEMBL17544709 0.77 GAA (0.60) ALDH1A1HPGDKDM4ENPSR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7838529-B2 Xanthine derivates, their preparation and their use in pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-23 — — US claimed
US-20090131432-A1 XANTHINE DERIVATES, THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-05-21 — — US claimed
US-7495005-B2 Xanthine derivatives, their preparation and their use in pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-02-24 — — US claimed
EP-1554278-B1 XANTHINE DERIVATIVES, PRODUCTION THEREOF AND USE THEREOF AS MEDICINES BOEHRINGER INGELHEIM PHARMA (DE) 2006-04-12 — — EP claimed
US-20040166125-A1 Xanthine derivatives, their preparation and their use in pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-08-26 — — US claimed
US-7838529-B2 Xanthine derivates, their preparation and their use in pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-23 — — US disclosed
US-20090131432-A1 XANTHINE DERIVATES, THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-05-21 — — US disclosed
US-7495005-B2 Xanthine derivatives, their preparation and their use in pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-02-24 — — US disclosed
EP-1554278-B1 XANTHINE DERIVATIVES, PRODUCTION THEREOF AND USE THEREOF AS MEDICINES BOEHRINGER INGELHEIM PHARMA (DE) 2006-04-12 — — EP disclosed
EP-1554278-A2 XANTHINE DERIVATIVES, PRODUCTION THEREOF AND USE THEREOF AS MEDICINES BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-07-20 — — EP disclosed
US-20040166125-A1 Xanthine derivatives, their preparation and their use in pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-08-26 — — US disclosed
WO-2004018467-A2 PHENACYL XANTHINE DERIVATIVES AS DPP-IV INHIBITOR BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-03-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040166125-A1 Xanthine derivatives, their preparation and their use in pharmaceutical compositions XDH, CALCRL, CALCA ALDH1A1 160/4885HPGD 740/4885KDM4E 2704/4885
US-20090131432-A1 XANTHINE DERIVATES, THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS XDH, CALCRL, GPR119 ALDH1A1 274/4885HPGD 776/4885KDM4E 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback